

an international reproductive health journal

# Contraception

Volume 97, Number 2, February 2018

**Publication information:** *Contraception* (ISSN 0010-7824) is published monthly by Elsevier Inc., 230 Park Avenue, New York, NY 10169. Periodicals postage paid at New York, NY, and additional mailing offices.  
**USA POSTMASTER:** Send address changes to *Contraception*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

**Annual subscription rates:** United States and possessions: individual, \$503; institution, \$1,782. All other countries: individual, \$585; institution, \$1,875.

**Orders, claims, and journal inquiries:** Please visit our Support Hub page <https://service.elsevier.com> for assistance.

**Advertising information:** Advertising orders and inquiries can be sent to: USA, Canada and South America: Le-Andrea Sylvester, Elsevier Inc., 230 Park Avenue, New York, NY 10169. Tel.: (212) 633-3649, e-mail: [le.sylvester@elsevier.com](mailto:le.sylvester@elsevier.com).

**Reprints:** To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, New York, NY 10169; E-mail: [reprints@elsevier.com](mailto:reprints@elsevier.com).

**Author information:** For full and complete Author Information, please go to: <http://www.contraceptionjournal.org/authorinfo>.

**Author inquiries:** You can track your submitted article at <http://www.elsevier.com/track-submission>. You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://service.elsevier.com>.

**Funding body agreements and policies:** Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

© 2018 by Elsevier Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Inc., and the following terms and conditions apply to their use:


**Photocopying:** Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit [www.elsevier.com/permissions](http://www.elsevier.com/permissions) or call: (+44) 1865 843830 (UK)/(+1) 215 239 3804 (USA).

**Derivative Works:** Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations (please consult [www.elsevier.com/permissions](http://www.elsevier.com/permissions)).

**Electronic Storage or Usage:** Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult [www.elsevier.com/permissions](http://www.elsevier.com/permissions)). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

**Notice:** No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

 This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

## Special Edition: Medical Abortion

Guest Editors: Marge Berer and Lesley Hoggart

### Editorial

- 79 Medical Abortion Pills Have the Potential to Change Everything About Abortion

*Marge Berer, Lesley Hoggart*

### The potential of medical abortion

- 82 What if Medical Abortion Becomes the Main or Only Method of First-trimester Abortion? A Roundtable of Views

*Kevin Sunde Oppegaard, Margaret Sparrow, Paul Hyland, Francisca García, Cristina Villarreal, Anibal Faúndes, Laura Miranda, Marge Berer*

- 86 Putting Abortion Pills Into Women's Hands: Realizing the Full Potential of Medical Abortion

*Kinga Jelinska, Susan Yanow*

- 90 Efficacy of Medical Abortion Prior to 6 Gestational Weeks: A Systematic Review

*Nathalie Kapp, Maureen K. Baldwin, Maria Isabel Rodriguez*

### Women's experiences

- 100 Experience of Clandestine Use of Medical Abortion Among University Students in Chile: A Qualitative Study

*Irma Palma Manríquez, Claudia Moreno Standen, Andrea Álvarez Carimoney, Alondra Richards*

- 108 Accompaniment of Second-trimester Abortions: The Model of the Feminist Socorrista Network of Argentina

*Ruth Zurbriggen, Brianna Keefe-Oates, Caitlin Gerdts*

- 116 Complications With Use of Misoprostol for Abortion in Madagascar: Between Ease of Access and Lack of Information

*Dolorès Pourette, Chiarella Mattern, Rila Ratovoson, Patricia Raharimalala*

- 122 "It Is Just Like Having A Period With Back Pain": Exploring Women's Experiences With Community-based Distribution of Misoprostol for Early Abortion on the Thailand–Burma Border

*Ellen Tousaw, Sweet Naw Hser Gay Moo, Grady Arnott, Angel M. Foster*

(Contents continued)

- 130** Abortion in Two Francophone African Countries: A Study of whether Women Have Begun to Use Misoprostol in Benin and Burkina Faso  
*Carine Baxerres, Ines Boko, Adjara Konkobo, Fatoumata Ouattara, Agnès Guillaume*
- 137** **Pharmacy provision of medical abortion**  
Medical Abortion Can be Provided Safely and Effectively By Pharmacy Workers Trained Within A Harm Reduction Framework: Nepal  
*Anand Tamang, Mahesh Puri, Sazina Masud, Deepak Kumar Karki, Diksha Khadka, Minal Singh, Poonam Sharma, Subash Gajurel*
- 144** Provision of Menstrual Regulation With Medication Among Pharmacies in Three Municipal Districts of Bangladesh: A Situation Analysis  
*Fauzia Akhter Huda, Hassan Rushekh Mahmood, Anadil Alam, Faisal Ahmmed, Farzana Karim, Bidhan Krishna Sarker, Nafis Al Haque, Anisuddin Ahmed*
- 152** Feasibility of Assessing the Safety and Effectiveness of Menstrual Regulation Medications Purchased From Pharmacies in Bangladesh: A Prospective Cohort Study  
*Katharine Footman, Rachel Scott, Fahmida Taleb, Sally Dijkerman, Sadid Nuremowla, Kate Reiss, Kathryn Church*
- 160** **Role of the health system and healthcare providers**  
Provision of Medical Abortion By Midlevel Healthcare Providers in Kyrgyzstan: Testing An Intervention to Expand Safe Abortion Services to Underserved Rural and Periurban Areas  
*Brooke Ronald Johnson Jr, Elmira Maksutova, Aigul Boobekova, Ainura Davletova, Chinara Kazakbaeva, Yelena Kondrateva, Sihem Landoulsi, Gunta Lazdane, Kubanychbek Monolbaev, Armando H. Seuc Jo*
- 167** Doing More for Less: Identifying Opportunities to Expand Public Sector Access to Safe Abortion in South Africa Through Budget Impact Analysis  
*Naomi Lince-Deroche, Jane Harries, Deborah Constant, Chelsea Morroni, Melanie Pleaner, Tamara Fetters, Daniel Grossman, Kelly Blanchard, Edina Sinanovic*

(Continued)

(Contents continued)

- 177** Barriers to Accessing Abortion Services and Perspectives on Using Mifepristone and Misoprostol At Home in Great Britain

*Abigail R.A. Aiken, Katherine A. Guthrie, Marlies Schellekens, James Trussell, Rebecca Gomperts*

**A forward-looking research agenda**

- 184** Developing A Forward-looking Agenda and Methodologies for Research of Self-use of Medical Abortion

*Nathalie Kapp, Kelly Blanchard, Ernestina Coast, Bela Ganatra, Jane Harries, Katharine Footman, Ann Moore, Onikepe Owolabi, Clementine Rossier, Kristen Shellenberg, Britt Wahlin, Cynthia Woodsong*